GOVX up 15%/~300k shares at close.

Anybody get the link to the most recent GOVX Tweet? CEO at 1:58: "Tremendous progress being made to treat Covid-19"

Trompete, you are probably right and certainly rational...but take a look around. When you find something that looks rational in the markets, let me know. Take Moderna, sketchy execs & potentially bad science, it's just humming along with tons of optimism & media. The threshold to making money under the guise of COVID-19 vaccine development is pretty low.

GOVX offers fantastic risk/reward outcomes. It's that simple.

There is a chance, albeit slim, that OTCQB approval was a condition of funding (most likely private funding). GLTA.

It's a great question. My two cents: I think funding will be awarded regardless. If/when they produce a viable drug candidate, things may be "restructured." These are good problems for others to deal in a post 10$ PPS world.

GLTA. Fruitful week(s) ahead.

RFB, what platform allows you to short OTCs? Thanks.

http://www.cbsnews.com/videos/the-zika-virus/

Free viewing has "timed-out" but for those who have not seen it...it's worth the $10/year.

GUIRAKHOO

Prior to joining Vaxess, Dr. Guirakhoo was Chief Scientific Officer of Vienna, Austria-based Hookipa Biotech, where he led the development of a novel vaccine platform. Dr. Guirakhoo spearheaded preclinical and early GMP manufacturing development for the company's lead vaccine candidate, helping the company raise €20 million in venture financing. Dr. Guirakhoo previously served as Senior Director of External R&D for Sanofi Pasteur, where he evaluated companies worldwide for collaboration, licensing, and M&A. Prior to Sanofi's acquisition of Acambis, he led the latter company's Department of Virology, where he coordinated the development of multiple vaccines (including IMOJEV, a marketed vaccine for Japanese encephalitis, and late clinical-stage vaccines for West Nile disease and dengue fever) and co-invented the ChimeriVax platform.

http://www.fiercepharma.com/vaccines/farshad-guirakhoo-joins-vaxess-technologies-as-chief-technology-officer

Today's news is a good indicator that grant money has been awarded and program managers have been named.If so, I suspect they will hold the news (if they can) until JPMorgan Conf.

Per JPM press release "The Company will provide an update on its vaccine development programs..."

Time will tell but clarifying roles and future responsibilities is (IMO) a good sign.

GOVX has 2.5M market cap. and aggressively seeks grant funding for RD.

There is a chance that:
http://www.cbsnews.com/videos/the-zika-virus/

Is this:
http://www.geovax.com/news-events/entry/2010/10/07/geovax-labs-announces-issuance-of-6th-patent.html

And if so, Zika may demonstrate GOVX's effective delivery platform for multiple viruses.

Regarding 60 Minutes:
http://www.cbsnews.com/videos/the-zika-virus/

The shoe does seem to be fitting:
http://www.geovax.com/news-events/entry/2010/10/07/geovax-labs-announces-issuance-of-6th-patent.html

I'm going to redo our landing page. let me know if you guys have things to post.

no timestamp. about 3/4 of the way through.

Encouraging but not exclusive:

http://www.who.int/csr/research-and-development/zika-rd-pipeline.pdf

Here is a link to the 60 mins video: http://www.cbsnews.com/videos/the-zika-virus/

I am assuming what Remind2 is referring to is the "VLP" (virus like particle) labeling.

UGA looking to hire Program Manager for the Zika Program in the Center for Vaccines and Immunology (CVI).

https://careers.insidehighered.com/job/1271749/assistant-research-scientist-cvi-zika-program/

Two more confirmed Zika cases

http://www.news4jax.com/health/zika-virus/two-more-women-diagnosed-with-zika

NOV 2016 should be a good month for GOVX

"The Investigational New Drug (IND) application for HVTN 114 was filed by NIAID on June 28, 2016, and we expect the trial to begin patient enrollment in November 2016."

per 10K

as a moderator.

I will upload some of the slides

I have a presentation from Dr. McNally.

Greetings GOVX board. Gonna do a few uninformative posts for Mod. status.

Press Releases

Amarantus Announces Capital Infusion

Download as PDF
APRIL 21, 2016
SAN FRANCISCO, April 21, 2016 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, has entered into a Securities Purchase Agreement (the "SPA") with three existing institutional investors for the sale of an aggregate principal amount $1,500,000 (including 10% OID) 10% Senior Secured Convertible Promissory Notes due April 17, 2017 (the "Notes") and a warrant to purchase 1,350,000 shares of common stock (the "Warrant") in a private placement offering. Pursuant to the SPA, the investors agreed to purchase additional aggregate principal amount of $1,555,556 (including 10% OID) of Notes and Warrants to purchase 1,400,000 shares of common stock upon effectiveness of a registration statement (the "Registration Statement") registering the common stock underlying the Notes and Warrants or earlier as mutually agreed between the investors and the Company and an additional $1,388,889 (including 10% OID) of Notes and Warrants to purchase 1,250,000 shares of common stock on the 61st day after effectiveness of the Registration Statement or earlier as mutually agreed between the investors and the Company. The first funding tranche of $1.35M has been delivered to the Company, with the primary use of proceeds to finance the Company's development of the ESS program. The Company is required to file the Registration Statement by April 29th, 2016.

Chardan Capital Markets, LLC acted as sole placement agent for the transaction.

"We are in preparation mode for the initiation of the Phase 2 clinical study for ESS in collaboration with the US Army," said Gerald E. Commissiong, President & CEO of Amarantus. "This capital investment positions Amarantus to be operationally ready to open the clinical study shortly."

The Notes, Warrants and shares issuable upon conversion of the Notes and exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of Neurology, Regenerative Medicine and Orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS), an autologous full thickness skin replacement product in development for the treatment of adult severe burns, currently preparing to enter Phase 2 clinical studies. In parallel, the Company is evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas. ESS has achieved Orphan Drug Designation (ODD) in the area of severe burns, and is seeking ODD status for additional serious dermatologic indications. AMBS also has development rights to eltoprazine, a small molecule currently in clinical development for Parkinson's disease levodopa-induced dyskinesia, an orphan disorder, with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP) and retinal artery occlusion (RAO). AMBS also owns the technology platform that led to MANF's discovery (PhenoGuard™), and which can be used to identify novel neurotrophic factors.

AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing-based test for identifying patients with relapsing-remitting multiple sclerosis at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, (developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig), and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Amarantus Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com



SOURCE Amarantus BioScience Holdings, Inc.

Released April 21, 2016

Shareholders and pps have never been on his radar. His has done quite well for himself...and that is how he measures success.

"100 to zero real quick"

Considered that AMBS is swirling the drain, can we buy back our 40% at a discount?

for Winnie the Pooh? you can't trap toxic debt. you write a check with clean money. there is no magic or secret.

There is a slim chance that AVDX (a competent company) will find CLEAN funding to buyback their 40%...and likely at a discount because GC is GC.

Will it be enough to pay off toxics and avoid another RS? I think so. Will AMBS be of shell of what it once was...I know so.

To the oldtimers here, what happened to NuroPro? My search has shown a dead-end with the RBCC deal...but nothing conclusive.

Not good.

I agree. There is so much at stake, so much at risk...that I'm optimistic.

It really is make or break time for GC. If break, I think you would agree that the IP alone justifies our current MC.

I suspect a PR on new financing by mid-week (i.e. we are witnessing a bear trap/encouraging toxic sell-off).

GLTA

IMO the last hour of trading will indicate the value of this LOI/Dx spinoff. I lean towards a bounce that leaves us down 10-12%

45% is 45%. Private or public. Look at their management, they are in it for licensing. Amen to a revenue focused business model that takes on the cost of AMBS Dx.

Now, GC needs clean money and MAYBE this is a condition of getting it.

Avant's IP http://www.avantdiagnostics.com/about/patents

on 1200 volume : (

AVDX up 120%

Good luck with that Dr. Frost...or is it just Sandy?

blue chip taste and pink sheet wallet.

I understand that GC is not in the good graces of many here, however what we are not hearing may be a positive. Not tweeting, not releasing soft bs PRs, not kicking the can into next quarter, is a deviation from the norm...and is the best indication that that things are happening and he is now required to keep his mouth shut.

gtla